Cemiplimab to treat cervical cancer

Cemiplimab (Cemiplimab) contains the active substance cemiplimab and is used to treat recurrent or metastatic cervical cancer in patients whose disease has progressed during or after platinum-based chemotherapy. Cimepilimab belongs to a class of drugs called programmed cell death ligand 1 (PD-L1) antibodies. In a major study of 608 patients with recurrent or metastatic cervical cancer who had previously received platinum-based chemotherapy, patients who received cimipilimab lived about 12 months, compared with 8.5 months for those who received chemotherapy. On average, patients who received cimipilimab lived without worsening for 2.8 months, compared with 2.9 months for those who received chemotherapy.